甲癬市場規模、佔有率和成長分析（按類型、治療方法和地區分類）—2026-2033年產業預測

預計到 2024 年，全球甲癬市場規模將達到 55.4 億美元，到 2025 年將達到 57.9 億美元，到 2033 年將達到 82.3 億美元，在預測期（2026-2033 年）內，複合年成長率為 4.5%。

全球甲癬市場涵蓋了致力於診斷、治療和管理真菌性甲感染疾病的製藥和醫療保健領域。這種常見疾病會導致指甲變色、增厚和脆弱，進而可能引起不適和併發症。市場成長的主要促進因素包括人們對指甲健康的日益重視、與老齡化、糖尿病和免疫抑制等因素相關的甲癬發病率上升，以及診斷和治療方法的進步。該市場提供多種治療方案，包括外用和口服抗真菌藥物、指甲油以及清創和雷射治療設備。相關人員正專注於研究、產品發布和策略合作。對創新治療方法的需求不斷成長，正在推動北美、歐洲和亞太地區的市場擴張。

全球甲癬市場促進因素

推動全球甲癬市場發展的關鍵因素是各種風險因素的日益增多，例如糖尿病、老化、免疫系統減弱和指甲外傷。這些因素會增加真菌感染疾病的風險，導致需要進行甲癬診斷和治療的患者群體不斷擴大。隨著這些風險因素的日益普遍，對有效治療方法的需求持續成長，推動了市場的發展。此外，人們對真菌性感染疾病的認知不斷提高，也促使更多患者尋求醫療干預和預防措施。

限制全球甲癬市場發展的因素

全球甲癬市場的主要阻礙因素是現有治療方法的潛在副作用和限制。雖然口服抗真菌藥物已被證實有效，但它們可能引起全身性副作用，並且需要密切監測以確保患者安全。此外，局部治療在處理嚴重或深部感染疾病時往往效果不佳，這給成功治療設置了障礙。這些挑戰不僅阻礙了市場擴張，也使為灰指甲患者提供安全有效的治療方案變得更加複雜，最終影響患者照護和治療的連續性。

全球甲癬治療市場趨勢

全球甲癬市場正呈現出顯著的發展趨勢，這主要得益於市場對創新且易於使用的治療方法的需求不斷成長。患者和醫療服務提供者都在尋求能夠提高療效、縮短療程並增強患者治療依從性的療法。為此，業內相關人員正積極投資研發，推出包括先進外用製劑和專用甲油在內的創新配方。此外，雷射療法等先進技術的探索也標誌著治療方向正朝著更精準有效的方向發展，這凸顯了業界致力於滿足患者需求並改善真菌性感染疾病治療效果的決心。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球甲癬市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 遠端甲下甲癬
• 白色淺層甲癬
• 近端甲下甲癬
• 其他

全球甲癬市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 口服
• 外用藥物
• 其他

全球甲癬市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Bausch Health Companies Inc.（Canada）
• GSK plc（UK）
• Abbott（US）
• Pfizer Inc.（US）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Inc.（India）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi（France）
• Johnson & Johnson（US）
• Eli Lilly and Company（US）
• Mylan NV（US）
• Galderma SA（Switzerland）
• Valeant Pharmaceuticals International, Inc.（Canada）
• Sandoz International GmbH（Germany）
• Lupin Limited（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Aurobindo Pharma Limited（India）

結論與建議

Global Onychomycosis Market size was valued at USD 5.54 Billion in 2024 and is poised to grow from USD 5.79 Billion in 2025 to USD 8.23 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The global onychomycosis market encompasses the pharmaceutical and healthcare sectors dedicated to the diagnosis, treatment, and management of nail fungal infections. This common condition, which leads to nail discoloration, thickening, and brittleness, can result in discomfort and complications. Key drivers of market growth include heightened awareness of nail health, the rising incidence of onychomycosis linked to factors such as aging, diabetes, and immune suppression, alongside advancements in diagnostics and therapies. The market features a variety of treatment options, including topical and oral antifungals, nail lacquers, and devices for debridement and laser therapy. Major stakeholders engage in research, product launches, and strategic partnerships, while regions like North America, Europe, and Asia Pacific significantly contribute to market expansion as innovative treatment demand grows.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Market Segments Analysis

Global Onychomycosis Market is segmented by Type, Treatment and region. Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis and others. Based on Treatment, the market is segmented into Oral, Topical and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onychomycosis Market

A significant factor driving the global onychomycosis market is the rising incidence of various risk factors, including diabetes, an aging demographic, compromised immune systems, and instances of nail trauma. These conditions heighten the vulnerability to fungal infections, resulting in an expanding population of patients in need of diagnosis and treatment for onychomycosis. As these risk factors become more prevalent, the demand for effective therapeutic options continues to grow, thus propelling the market forward. The increasing awareness of fungal nail infections also plays a role in elevating the need for medical interventions and preventative measures among affected individuals.

Restraints in the Global Onychomycosis Market

A significant constraint in the Global Onychomycosis market stems from the potential side effects and limitations of existing treatment modalities. While oral antifungal medications are recognized for their effectiveness, they can lead to systemic side effects that necessitate close monitoring to ensure patient safety. Moreover, topical treatments often demonstrate reduced efficacy when addressing severe or deeply rooted infections, creating barriers to successful outcomes. These challenges not only impede market expansion but also complicate the provision of safe and effective treatment alternatives for individuals suffering from onychomycosis, ultimately impacting patient care and treatment adherence.

Market Trends of the Global Onychomycosis Market

The global onychomycosis market is witnessing a significant trend driven by the increasing demand for innovative and user-friendly treatment options. Patients and healthcare providers are seeking therapies that not only enhance efficacy and shorten treatment times but also improve overall adherence to treatment regimens. In response, industry players are actively investing in research and development efforts to introduce groundbreaking formulations, including advanced topical solutions and specialized lacquers. Additionally, the exploration of cutting-edge technologies such as laser therapy indicates a shift towards more precise and effective treatments, underscoring the sector's dedication to addressing patient needs and improving outcomes in combating fungal nail infections.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Onychomycosis Market Size by Type & CAGR (2026-2033)

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• others

Global Onychomycosis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• others

Global Onychomycosis Market Size & CAGR (2026-2033)

• North America (Type, Treatment)
  • US
  • Canada
• Europe (Type, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International, Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations